From: Proteomic analysis in lupus mice identifies Coronin-1A as a potential biomarker for lupus nephritis
KEGG pathway | KEGG ID | Hits | p value | FDR |
---|---|---|---|---|
12 weeks | ||||
Metabolic pathways | mmu01100 | 483 | 1.45E−62 | 1.92E−61 |
Biosynthesis of antibiotics | mmu01130 | 144 | 4.13E−52 | 5.47E−51 |
Carbon metabolism | mmu01200 | 85 | 6.32E−35 | 8.38E−34 |
Oxidative phosphorylation | mmu00190 | 94 | 4.13E−34 | 5.48E−33 |
Parkinson’s disease | mmu05012 | 91 | 4.78E−28 | 6.35E−27 |
Alzheimer’s disease | mmu05010 | 94 | 8.33E−23 | 1.11E−21 |
Ribosome | mmu03010 | 82 | 2.94E−22 | 3.90E−21 |
Huntington’s disease | mmu05016 | 97 | 2.92E−20 | 3.88E−19 |
Valine, leucine and isoleucine degradation | mmu00280 | 43 | 1.66E−19 | 2.20E−18 |
Glycolysis/gluconeogenesis | mmu00010 | 47 | 1.46E−18 | 1.93E−17 |
Pyruvate metabolism | mmu00620 | 33 | 8.28E−17 | 1.44E−15 |
Non-alcoholic fatty liver disease (NAFLD) | mmu04932 | 75 | 5.96E−15 | 7.95E−14 |
Propanoate metabolism | mmu00640 | 25 | 1.82E−14 | 2.42E−13 |
Biosynthesis of amino acids | mmu01230 | 46 | 3.93E−14 | 5.21E−13 |
Fatty acid degradation | mmu00071 | 35 | 6.34E−14 | 8.41E−13 |
Peroxisome | mmu04146 | 48 | 1.10E−13 | 1.46E−12 |
Citrate cycle (TCA cycle) | mmu00020 | 27 | 1.15E−13 | 1.53E−12 |
Proteasome | mmu03050 | 33 | 1.18E−13 | 1.56E−12 |
Glutathione metabolism | mmu00480 | 36 | 1.39E−12 | 1.84E−11 |
Glycine, serine and threonine metabolism | mmu00260 | 28 | 6.95E−11 | 9.22E−10 |
24 weeks | ||||
Metabolic pathways | mmu01100 | 490 | 1.27E−57 | 1.69E−56 |
Biosynthesis of antibiotics | mmu01130 | 144 | 4.10E−49 | 5.45E−48 |
Carbon metabolism | mmu01200 | 87 | 3.25E−35 | 4.32E−34 |
Oxidative phosphorylation | mmu00190 | 97 | 5.63E−35 | 7.49E−34 |
Parkinson’s disease | mmu05012 | 96 | 2.40E−30 | 3.19E−29 |
Alzheimer’s disease | mmu05010 | 98 | 9.13E−24 | 1.21E−22 |
Huntington’s disease | mmu05016 | 102 | 1.41E−21 | 1.88E−20 |
Ribosome | mmu03010 | 82 | 9.71E−21 | 1.29E−19 |
Glycolysis/gluconeogenesis | mmu00010 | 50 | 1.35E−20 | 1.79E−19 |
Valine, leucine and isoleucine degradation | mmu00280 | 43 | 1.30E−18 | 1.72E−17 |
Pyruvate metabolism | mmu00620 | 34 | 2.25E−17 | 2.99E−16 |
Propanoate metabolism | mmu00640 | 26 | 1.88E−15 | 2.51E−14 |
Fatty acid degradation | mmu00071 | 37 | 3.48E−15 | 4.57E−14 |
Biosynthesis of amino acids | mmu01230 | 47 | 4.93E−14 | 6.55E−13 |
Citrate cycle (TCA cycle) | mmu00020 | 27 | 4.22E−13 | 5.60E−12 |
Proteasome | mmu03050 | 33 | 5.43E−13 | 7.22E−12 |
Non-alcoholic fatty liver disease (NAFLD) | mmu04932 | 73 | 1.26E−12 | 1.67E−11 |
Peroxisome | mmu04146 | 47 | 4.19E−12 | 5.57E−11 |
Glutathione metabolism | mmu00480 | 36 | 6.85E−12 | 9.10E−11 |
Fatty acid metabolism | mmu01212 | 32 | 5.96E−10 | 7.93E−09 |
36 weeks | ||||
Metabolic pathways | mmu01100 | 539 | 3.89E−63 | 5.17E−62 |
Biosynthesis of antibiotics | mmu01130 | 152 | 3.49E−50 | 4.64E−49 |
Carbon metabolism | mmu01200 | 94 | 6.45E−39 | 8.58E−38 |
Oxidative phosphorylation | mmu00190 | 100 | 1.22E−33 | 1.62E−32 |
Parkinson’s disease | mmu05012 | 95 | 1.04E−25 | 1.38E−24 |
Ribosome | mmu03010 | 90 | 3.47E−23 | 4.61E−22 |
Alzheimer’s disease | mmu05010 | 101 | 4.65E−22 | 6.18E−21 |
Glycolysis/gluconeogenesis | mmu00010 | 49 | 1.58E−17 | 2.10E−16 |
Huntington’s disease | mmu05016 | 101 | 1.91E−17 | 2.54E−16 |
Valine, leucine and isoleucine degradation | mmu00280 | 43 | 8.57E−17 | 1.44E−15 |
Biosynthesis of amino acids | mmu01230 | 52 | 4.61E−16 | 5.88E−15 |
Pyruvate metabolism | mmu00620 | 34 | 6.83E−16 | 8.88E−15 |
Proteasome | mmu03050 | 36 | 1.35E−14 | 1.80E−13 |
Non-alcoholic fatty liver disease (NAFLD) | mmu04932 | 81 | 2.34E−14 | 3.11E−13 |
Propanoate metabolism | mmu00640 | 25 | 7.73E−13 | 1.03E−11 |
Fatty acid degradation | mmu00071 | 36 | 1.04E−12 | 1.39E−11 |
Glutathione metabolism | mmu00480 | 38 | 4.26E−12 | 5.66E−11 |
Citrate cycle (TCA cycle) | mmu00020 | 27 | 5.98E−12 | 7.95E−11 |
Peroxisome | mmu04146 | 49 | 1.09E−11 | 1.45E−10 |
Fatty acid metabolism | mmu01212 | 34 | 3.02E−10 | 4.01E−09 |